# Pupillary Changes as a Potential Biomarker for Escitalopram in Relation to CYP2C19 Polymorphism

> **NCT00397059** · PHASE4 · COMPLETED · sponsor: **University of Southern Denmark** · enrollment: 16 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Escitalopram

## Key facts

- **NCT ID:** NCT00397059
- **Lead sponsor:** University of Southern Denmark
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2008-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00397059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00397059, "Pupillary Changes as a Potential Biomarker for Escitalopram in Relation to CYP2C19 Polymorphism". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00397059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*